Financial Statements · From SEC 10-K & 10-Q XBRL Filings
CVS Health Corporation Revenue & Financial Statements
CVS Health Corporation reported revenue of $402.1B for the fiscal year ended December 31, 2025, up 7.8% year over year, with net income of $1.7B and diluted EPS of $1.39.
- Company
- CVS Health Corporation CVS · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 292.1B | 322.5B | 357.8B | 372.8B | 402.1B |
| Cost of revenue | 175.8B | 196.9B | 217.1B | 206.3B | 221.2B |
| Gross profit | 116.3B | 125.6B | 140.7B | 166.5B | 180.9B |
| Operating income | 13.2B | 7.7B | 13.7B | 8.5B | 4.7B |
| Pretax income | 10.4B | 5.6B | 11.2B | 6.1B | 801.0M |
| Net income | 7.5B | 1.7B | 9.3B | 4.8B | 1.7B |
| Diluted EPS | 5.95 | 3.14 | 6.47 | 3.66 | 1.39 |
| EBITDA | 17.7B | 12.0B | 18.1B | 13.1B | 9.3B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 88.4B | 91.2B | 95.4B | 97.7B | 94.6B | 98.9B | 102.9B | 105.7B |
| Cost of revenue | 48.1B | 50.0B | 52.9B | 55.3B | 51.1B | 54.0B | 57.0B | 59.1B |
| Gross profit | 40.4B | 41.2B | 42.5B | 42.4B | 43.5B | 44.9B | 45.8B | 46.6B |
| Operating income | 2.3B | 3.0B | 832.0M | 2.4B | 3.4B | 2.4B | (3.2B) | 2.1B |
| Pretax income | 1.6B | 2.3B | 105.0M | 2.1B | 2.6B | 1.6B | (3.5B) | 1.4B |
| Net income | 1.1B | 1.8B | 615.0M | 1.3B | 2.0B | 1.2B | (3.8B) | 2.9B |
| Diluted EPS | 0.88 | 1.41 | 0.07 | 1.31 | 1.41 | 0.80 | -3.13 | 2.32 |
| EBITDA | 3.4B | — | 2.0B | 3.5B | 4.5B | 3.6B | (2.1B) | 3.3B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 233.0B | 228.3B | 249.7B | 253.2B | 253.5B |
| Current assets | 60.0B | 65.7B | 67.9B | 68.6B | 74.7B |
| Cash & equivalents | 9.4B | 12.9B | 8.2B | 8.6B | 8.5B |
| Total liabilities | 157.6B | 157.0B | 173.1B | 177.5B | 178.2B |
| Current liabilities | 67.8B | 69.7B | 79.2B | 84.6B | 88.7B |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | 200.0M | 2.1B | 0 |
| Stockholders’ equity | 75.1B | 71.0B | 76.5B | 75.6B | 75.2B |
| Net debt | — | — | (8.0B) | (6.5B) | (8.5B) |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 18.3B | 16.2B | 13.4B | 9.1B | 10.6B |
| Investing cash flow | (5.3B) | (5.0B) | (20.9B) | (7.6B) | (5.9B) |
| Financing cash flow | (11.4B) | (10.5B) | 2.7B | (1.1B) | (4.9B) |
| Capital expenditure | 2.5B | 2.7B | 3.0B | 2.8B | 2.8B |
| Free cash flow | 15.7B | 13.4B | 10.4B | 6.3B | 7.8B |
| Dividends paid | 2.6B | 2.9B | 3.1B | 3.4B | 3.4B |
| Stock-based compensation | 484.0M | 447.0M | 588.0M | 540.0M | 535.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every CVS filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.